Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Generation of New Bone Depends on WNT Stimulation of the mTORC1 Pathway

By BiotechDaily International staff writers
Posted on 18 Feb 2014
Image: As seen through a microscope, the leg bone of a normal mouse (left) makes considerably less new bone than a mouse that produces high levels of a signaling protein, WNT7B, that stimulates new bone growth (shown in pink on the right). The protein could become a target for new drugs to treat osteoporosis and other conditions related to bone loss (Photo courtesy of Washington University School of Medicine).
Image: As seen through a microscope, the leg bone of a normal mouse (left) makes considerably less new bone than a mouse that produces high levels of a signaling protein, WNT7B, that stimulates new bone growth (shown in pink on the right). The protein could become a target for new drugs to treat osteoporosis and other conditions related to bone loss (Photo courtesy of Washington University School of Medicine).
The WNT signaling protein WNT7B potently enhances formation of new bone through activation of mTORC1 (mammalian target of rapamycin) in a mouse osteoporosis model.

Previous studies have implicated WNT signaling in both embryonic and postnatal bone formation. However, the pertinent WNT ligands and their downstream signaling mechanisms are not well understood.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) used several lines of genetically engineered mice to examine the role of WNT signaling in bone formation.

The WNT gene family consists of structurally related genes that encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. The WNT pathway involves a large number of proteins that can regulate the production of WNT signaling molecules, their interactions with receptors on target cells, and the physiological responses of target cells that result from the exposure of cells to the extracellular WNT ligands. Although the presence and strength of any given effect depends on the WNT ligand, cell type, and organism, some components of the signaling pathway are remarkably conserved in a wide variety of organisms.

Results published in the January 30, 2014, online edition of the journal PLOS Genetics revealed that WNT7B protein increased bone mass by stimulating formation of bone-building osteoblast cells while having no effect on the activity of bone-degrading osteoclasts. At the molecular level, it was seen that WNT7B exerted its effects through activation of the mTORC1 pathway. MTORC1 is a serine/threonine protein kinase of the phosphatidylinositol 3-kinase (PI3K) protein family that regulates cell growth, proliferation, motility, survival, protein synthesis, and transcription.

Genetic disruption of mTORC1 signaling prevented the WNT7B-induced formation of high-bone-mass phenotype mice.

“We have been looking for new ways to stimulate bone formation,” said senior author Dr. Fanxin Long, professor of medicine and developmental biology at the Washington University School of Medicine. “The tools we already have are very good at slowing the breakdown of bone, but we need better ways to stimulate new bone growth. By analyzing that information, mTOR can determine whether a cell should go into a mode to make lots of stuff, like proteins or, in this case, new bone. Bone formation is an energetically expensive process, so it makes sense that some regulator would tell a cell whether there is sufficient energy and material to manufacture new bone. It is still early, but our finding seems to point out that activating the mTOR pathway may be a good way to stimulate bone growth. This is a new twist because much of the current focus in mTOR-related drug development has been on compounds that inhibit the pathway to shut down cancer cells.”

Patients, such as organ transplant recipients, who have been treated with immunosuppressive drugs that inhibit the mTOR pathway often present with bone problems. “Many develop bone problems within a few months of receiving transplants because of the heavy doses of immunosuppressors they receive,” said Dr. Long. “Scientists have not looked carefully at how drugs used to prevent organ rejection can have a detrimental effect on bone, but our study would suggest that if those drugs inhibit mTOR, they could disrupt bone formation.”

Related Links:

Washington University School of Medicine



Channels

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.